Presidio Property Trustの空売り状況は、投資家がPresidio Property Trustの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Presidio Property Trust (NASDAQ:SQFTP) 株価情報, 空売り情報

Presidio Property Trust

Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.

Presidio Property Trust, Inc. - 9.375% Series D Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share

Presidio Property Trust Inc

Truist Securities analyst Joon Lee maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $76 to $150.

News

Price Target

Analyst Ratings

CORT

Truist Securities Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

Financial giants have made a conspicuous bullish move on Corcept Therapeutics. Our analysis of options history for Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) revealed 38 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 34% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $282,776, and 34 were calls, valued at $3,592,834.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $110.0 for Corcept Therapeutics, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Corcept Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Corcept Therapeutics's significant trades, within a strike price range of $20.0 to $110.0, over the past month.
<h3>Corcept Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743439542_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$22.9</td>
<td>$20.2</td>
<td>$20.6</td>
<td>$95.00</td>
<td>$412.0K</td>
<td align="right">0</td>
<td align="right">201</td>
</tr>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$34.3</td>
<td>$31.3</td>
<td>$32.7</td>
<td>$90.00</td>
<td>$317.1K</td>
<td align="right">726</td>
<td align="right">200</td>
</tr>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$32.5</td>
<td>$31.5</td>
<td>$31.5</td>
<td>$90.00</td>
<td>$315.0K</td>
<td align="right">726</td>
<td align="right">300</td>
</tr>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$31.7</td>
<td>$28.3</td>
<td>$28.3</td>
<td>$90.00</td>
<td>$283.0K</td>
<td align="right">726</td>
<td align="right">100</td>
</tr>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$24.3</td>
<td>$22.0</td>
<td>$22.32</td>
<td>$100.00</td>
<td>$220.6K</td>
<td align="right">91</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About Corcept Therapeutics</h3>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
After a thorough review of the options trading surrounding Corcept Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Corcept Therapeutics</h3>
<ul>
<li>With a trading volume of 8,640,882, the price of CORT is up by 85.93%, reaching $101.57.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 30 days from now.</li>
</ul>
<h3>What The Experts Say On Corcept Therapeutics</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $150.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from HC Wainwright &amp; Co. continues to hold a Buy rating for Corcept Therapeutics, targeting a price of $150. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Corcept Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Corcept Therapeutics's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bullish stance on Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OXY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Occidental Petroleum.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 33%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $344,322, and 6 are calls, for a total amount of $288,910.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $75.0 for Occidental Petroleum over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Occidental Petroleum's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Occidental Petroleum's significant trades, within a strike price range of $40.0 to $75.0, over the past month.
<h3>Occidental Petroleum Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743439537_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$2.83</td>
<td>$2.75</td>
<td>$2.83</td>
<td>$42.50</td>
<td>$174.3K</td>
<td>2.9K</td>
<td align="right">616</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$2.17</td>
<td>$2.09</td>
<td>$2.17</td>
<td>$40.00</td>
<td>$142.7K</td>
<td>829</td>
<td align="right">658</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$2.14</td>
<td>$2.07</td>
<td>$2.14</td>
<td>$65.00</td>
<td>$86.2K</td>
<td>176</td>
<td align="right">403</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$6.05</td>
<td>$6.0</td>
<td>$6.05</td>
<td>$50.00</td>
<td>$60.5K</td>
<td>1.3K</td>
<td align="right">101</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.25</td>
<td>$52.50</td>
<td>$45.9K</td>
<td>5.8K</td>
<td align="right">123</td>
</tr>
</tbody>
</table>

<h3>About Occidental Petroleum</h3>
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,327 thousand barrels of oil equivalent per day in 2024 at a ratio of roughly 50% oil and natural gas liquids and 50% natural gas.
Having examined the options trading patterns of Occidental Petroleum, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Occidental Petroleum</h3>
<ul>
<li>With a volume of 3,998,828, the price of OXY is up 1.33% at $49.48. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>Expert Opinions on Occidental Petroleum</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $55.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from JP Morgan persists with their Neutral rating on Occidental Petroleum, maintaining a target price of $52. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Occidental Petroleum with a target price of $50. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Occidental Petroleum, targeting a price of $58. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Occidental Petroleum, maintaining a target price of $51. 
&#x2A; An analyst from Raymond James has revised its rating downward to Outperform, adjusting the price target to $64. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Occidental Petroleum with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Occidental Petroleum's Options Frenzy: What You Need to Know

Financial giants have made a conspicuous bullish move on United States Steel. Our analysis of options history for United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) revealed 16 unusual trades.
Delving into the details, we found 43% of traders were bullish, while 31% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $408,964, and 9 were calls, valued at $310,980.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $39.0 to $52.5 for United States Steel over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in United States Steel's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to United States Steel's substantial trades, within a strike price spectrum from $39.0 to $52.5 over the preceding 30 days.
<h3>United States Steel Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743439532_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.3</td>
<td>$12.1</td>
<td>$12.1</td>
<td>$52.50</td>
<td>$79.8K</td>
<td align="right">148</td>
<td align="right">66</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.35</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$52.50</td>
<td>$79.2K</td>
<td align="right">148</td>
<td align="right">132</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.3</td>
<td>$5.15</td>
<td>$5.3</td>
<td>$43.00</td>
<td>$57.7K</td>
<td align="right">25</td>
<td align="right">109</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.9</td>
<td>$10.5</td>
<td>$10.5</td>
<td>$50.00</td>
<td>$57.7K</td>
<td align="right">695</td>
<td align="right">55</td>
</tr>
<tr>
<td>X</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.65</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$50.00</td>
<td>$57.2K</td>
<td align="right">695</td>
<td align="right">110</td>
</tr>
</tbody>
</table>

<h3>About United States Steel</h3>
United States Steel Corp operates in the United States but also has a steelmaking capacity in Slovakia. The company's operating segments include North American Flat-Rolled (Flat-Rolled), Mini Mill, U. S. Steel Europe (USSE), and Tubular Products (Tubular). The Flat-Rolled segment includes U. S. Steel's integrated steel plants and equity investees in North America involved in the production of slabs, strip mill plates, sheets, and tin mill products, as well as all iron ore and coke production facilities in the United States. It serves North American customers in the service center, conversion, transportation, construction, container, and appliance, and electrical markets.
<h3>Present Market Standing of United States Steel</h3>
<ul>
<li>Trading volume stands at 2,005,917, with X's price down by -3.02%, positioned at $41.7.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 31 days.</li>
</ul>
<h3>What Analysts Are Saying About United States Steel</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $44.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from BMO Capital persists with their Outperform rating on United States Steel, maintaining a target price of $45. 
&#x2A; Reflecting concerns, an analyst from BMO Capital lowers its rating to Market Perform with a new price target of $45. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on United States Steel, maintaining a target price of $43. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on United States Steel, which currently sits at a price target of $43. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for United States Steel with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in United States Steel

Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) has outperformed the market over the past 5 years by 26.96% on an annualized basis producing an average annual return of 44.4%. Currently, Tapestry has a market capitalization of $15.96 billion. 
Buying $1000 In TPR: If an investor had bought $1000 of TPR stock 5 years ago, it would be worth $6,323.34 today based on a price of $68.50 for TPR at the time of writing.
<h3>Tapestry's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743439516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Needham analyst David Saxon reiterates CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) with a Buy and maintains $11 price target.

Reiteration

CYRX

Needham Reiterates Buy on CryoPort, Maintains $11 Price Target

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), on Sunday, announced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44552764/lillys-lepodisiran-reduced-levels-of-genetically-inherited-heart-disease-risk-factor-lipoprotein-a" rel="noreferrer noopener">positive Phase 2 results</a> for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.
In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint.
Participants who received the 16 mg and 96 mg lepodisiran doses experienced a 40.8% reduction and a 75.2% reduction in Lp(a) levels over the same time period, respectively.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44544761/european-drug-regulator-gives-thumbs-down-to-eli-lillys-alzheimers-drug-analyst-says-it-is-incremental-win-for-biogen" rel="noreferrer noopener">European Drug Regulator Gives Thumbs Down To Eli Lilly&#8217;s Alzheimer&#8217;s Drug, Analyst Says It Is Incremental Win For Biogen</a>
Lepodisiran also met additional secondary endpoints, showing reductions in Lp(a) levels following one or two administrations of each of the three tested doses across all timepoints assessed throughout the nearly 18-month-long study.
Results from additional secondary endpoints showed:
<ul>
<li>Participants who received 400 mg of lepodisiran at both baseline and day 180 experienced a 94.8% reduction in average Lp(a) levels over the day 30 to 360 period, which remained 91.0% below baseline at day 360 (~1 year) and 74.2% below baseline at day 540 (~1.5 years).</li>
<li>Lepodisiran also reduced apolipoprotein B (apoB) levels, a separate cholesterol biomarker.</li>
<li>The highest dose (400 mg) of lepodisiran showed 14.1% and 13.7% ApoB reductions from baseline at day 60 and 180, respectively. A second 400 mg lepodisiran dose at day 180 sustained these apoB reductions through day 540.</li>
</ul>
Treatment-emergent adverse events (TEAEs) related to the study drug occurred in 1% (1/69) of the placebo group, 3% (1/36) of the 16 mg group, 12% (9/74) of the 96 mg group, and 14% (20/141) of the pooled 400 mg group. There were no serious adverse events related to lepodisiran treatment.
A single death occurred in the 16 mg dose group due to complications of chronic coronary disease.
One participant in the placebo group was withdrawn from the study drug due to a TEAE; however, no participants receiving lepodisiran experienced a TEAE leading to withdrawal from treatment or the study.
The ACCLAIM-Lp(a) Phase 3 clinical development program, investigating the effect of lepodisiran on the reduction of cardiovascular events in adults with elevated Lp(a), is currently enrolling.
Price Action: LLY stock is down 1.42% at $810.86 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44544107/rokus-next-chapter-analyst-sees-big-gains-from-streaming-and-ad-expansion" target="_blank" rel="noreferrer noopener">Roku&#8217;s Next Chapter: Analyst Sees Big Gains From Streaming And Ad Expansion</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%

Enovix Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) shares are trading lower. The company on Monday provided a progress update on its planned 2025 launch <a href="https://www.benzinga.com/pressreleases/25/03/g44560120/enovix-reports-progress-on-2025-smartphone-launch">with a smartphone OEM</a>.
What To Know: Enovix said it completed the second milestone under the development agreement it executed in October 2024 with a leading smartphone OEM, triggering a payment for shipped sample battery cells. 
Enovix noted that the samples were customized to meet specific requirements of the OEM, including cycle life, fast charge and energy density levels.
&#8220;I am pleased that our team continues to progress our most advanced smartphone agreement in-line with our aim for mass production late 2025,&#8221; said Raj Talluri, CEO of Enovix.
&#8220;Passing the ISO audit and receiving the certification was also a significant milestone, reflecting our deep commitment to quality in manufacturing operations.&#8221;
Enovix recently announced the completion of an ISO audit of Fab2 in Malaysia with no major or minor findings. The company on Monday said it received formal ISO certification last week. 
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44560485/goldman-sachs-slashes-sp-500-price-outlook-as-tariffs-weaker-growth-hit-earnings">Goldman Sachs Slashes S&amp;P 500 Price Outlook As Tariffs, Weaker Growth Hit Earnings</a>
ENVX Price Action: <a href="http://benzinga.com/quote/envx">Enovix shares</a> were down 3.01% at $7.25 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

ENVX

Enovix Stock Is Moving Lower Monday: What's Happening?

WIIM

AIG shares are trading higher after the company announced its board authorized the repurchase of $7.5 billion worth of stock.

NEXN

Nexxen International shares are trading higher after Scotiabank initiated its coverage on the stock with a Sector Outperform rating.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) with a Buy and maintains $8 price target.

CNTB

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $8 Price Target

Palatin Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) on Monday reported topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon-like peptide-1/gastric inhibitory polypeptide <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">(GLP-1/GIP) tirzepatide</a>.
Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide is available as Mounjaro and Zepbound for diabetes and weight loss.
Topline data results from the study were highly statistically significant for the study&#8217;s primary endpoint, which was percent weight loss in patients for the co-administration of MC4R agonist bremelanotide plus&nbsp;GLP-1/GLP tirzepatide compared to placebo, over the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44558732/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1gip-tirzepatide-meets-prima" rel="noreferrer noopener">8-week treatment period</a>.
<ul>
<li>The co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44536083/palatin-technologies-touts-positive-results-from-mid-stage-study-for-experimental-drug-for-ulcerative-colitis-halts-patients-enrollment-citing-strategic-focus" rel="noreferrer noopener">Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus</a>
The primary analysis for additive effect demonstrated that:
<ul>
<li>40% of patients in the co-administered group achieved a 5% reduction in their body weight, compared to 27% for the tirzepatide alone group.</li>
<li>27% of patients in the co-administered group achieved a 6% reduction in their body weight, compared to 13% for the tirzepatide alone group.</li>
<li>19% of patients in the co-administered group achieved a 7% reduction in their body weight, compared to 0% for the tirzepatide alone group.</li>
</ul>
Over 50% of the lost weight was regained within two weeks after treatment cessation in both the co-administration and the tirzepatide-only groups, a common occurrence following the discontinuation of&nbsp;GLP-1/GIP therapy.
The data indicated that weight regain was effectively halted in the MC4R agonist bremelanotide group.
Additionally, co-administration of the MC4R agonist with the&nbsp;GLP-1/GIP therapy showed no increase in safety or tolerability concerns among patients.
Further data analysis is ongoing, including exploratory endpoints such as body composition and body mass index.
Palatin is advancing the development of its next-generation MC4R long-acting peptide and oral small molecule compounds as stand-alone treatments, as well as in combination with&nbsp;GLP-1/GIP (incretin therapy), and as monotherapy for multiple genetic obesity disorders.
Investigational New Drug applications are expected to be submitted in the fourth quarter of calendar 2025, with clinical data expected in the first half of 2026.
Price Action: PTN stock is down 14.6% at $0.5656 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/emerging-markets/25/03/44563420/despite-us-expansion-taiwan-semiconductor-reaffirms-commitment-to-home-base-with-new-initiatives-reuters" target="_blank" rel="noreferrer noopener">Despite US Expansion, Taiwan Semiconductor Reaffirms Commitment To Home Base With New Initiatives: Reuters</a></li>
</ul>
Photo via Shutterstock.

Equities

Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight

Raymond James analyst C. Gregory Peters maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Outperform and raises the price target from $125 to $135.

Raymond James Maintains Outperform on The Hartford Insurance Gr, Raises Price Target to $135

Dividends

TJX Companies Raises Dividend From $0.38 To $0.425/Share

AuthID Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) shares are trading lower by 26.6% to $4.75 during Monday&#8217;s session after the company announced an <a href="https://www.benzinga.com/pressreleases/25/03/g44560119/authid-announces-pricing-of-approximately-8-150-000-million-registered-direct-offering">$8.15 million offering</a>.
What To Know: Denver-based biometric authentication firm AuthID has announced a registered direct offering, raising approximately $8.15 million through the sale of 1.81 million shares and pre-funded warrants at $4.50 each. The offering is expected to close by April 1.
AuthID is also forming an Advisory Board, featuring Eric Swider, CEO of Rubidex, and Donald Nitti, Founder of Chroma Ventures. Swider, a former DWAC CEO, praised authID's biometric authentication technology, while Nitti highlighted its potential across various industries.
CEO Rhon Daguro emphasized authID's commitment to combating fraud and deepfake threats. The proceeds from the offering will support working capital and corporate expansion.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44560485/goldman-sachs-slashes-sp-500-price-outlook-as-tariffs-weaker-growth-hit-earnings">Goldman Sachs Slashes S&amp;P 500 Price Outlook As Tariffs, Weaker Growth Hit Earnings</a>
<h2 class="wp-block-heading">How To Buy AUID Stock</h2>
By now you're likely curious about how to participate in the market for AuthID &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AUID has a 52-week high of $12.31 and a 52-week low of $4.01.

AUID

Why AuthID Shares Are Down More Than 25%

Raymond James analyst John Freeman maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Outperform and raises the price target from $46 to $55.

Raymond James Maintains Outperform on Range Resources, Raises Price Target to $55

Raymond James analyst Brian MacArthur maintains Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) with a Outperform and raises the price target from $23 to $23.5.

GOLD

Raymond James Maintains Outperform on Barrick Gold, Raises Price Target to $23.5

In a recent <a href="https://x.com/GrantCardone/status/1905388366050238952">post</a> on X, entrepreneur and real estate investor Grant Cardone fired off a direct message to critics of Elon Musk and his government agency, DOGE: &#8220;You guys opposing DOGE actually ARE NOT GOOD Americans.&#8221;
Cardone backed up his statement with a quote from Musk: &#8220;The sheer amount of waste and fraud in the government, it is astonishing — it&#8217;s mind-blowing. We routinely encounter wastes of $1 billion or more — casually.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">You guys opposing DOGE actually ARE NOT GOOD Americans. "The sheer amount of waste and fraud in the government, it is astonishing — it's mind boggling. We routinely encounter wastes of $1 billion or more — casually." Elon Musk <a href="https://t.co/vCxc5fgKm8">pic.twitter.com/vCxc5fgKm8</a>
&mdash; Grant Cardone (@GrantCardone) <a href="https://twitter.com/GrantCardone/status/1905388366050238952?ref_src=twsrc%5Etfw">March 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 billion startup investment boom: How this company's explosive growth is opening doors for everyday investors with a new $500 minimum</a></li>
</ul>
<h2 class="wp-block-heading">Musk Says DOGE is Saving the U.S. Billions</h2>
The comment comes on the heels of a wide-ranging Fox News <a href="https://www.youtube.com/watch?v=l7kQNwJ4H_w">interview</a> with Musk and his DOGE team, where they laid out the scope of government waste and what they're doing to stop it.
DOGE's goal is apparently to <a href="https://www.benzinga.com/startups/25/01/43046108/musks-doge-ambitions-shrink-why-2-trillion-budget-cuts-may-be-out-of-reach">cut the federal deficit by $1 trillion</a>. Musk said that means dropping the annual deficit from $2 trillion to $1 trillion and cutting federal spending from $7 trillion to $6 trillion by rooting out fraud and waste.
&#8220;We feel confident that a 15% reduction can be done without affecting any of the critical government services,&#8221; Musk said.
He shared a stunning example: a simple 10-question online survey about national parks, which could have been done with SurveyMonkey for $10,000. &#8220;The government was being charged almost a billion dollars for that,&#8221; he claimed. &#8220;A billion dollars for a simple online survey—Do you like the national park?&#8221;
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
<h2 class="wp-block-heading">Social Security, Medicare and What's Not Being Cut</h2>
Musk and the DOGE team pushed back hard against allegations that they're trying to cut Social Security or Medicare.
&#8220;Legitimate recipients of Social Security will receive more money, not less money,&#8221; Musk said. &#8220;Let the record show that I said this.&#8221;
The team said they are protecting benefits by cutting off fraud and fixing broken systems. They cited phone scams where 40% of Social Security calls are from fraud centers trying to reroute benefits.
See Also: This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a>
<h2 class="wp-block-heading">Cuban Pushes Back: Government Isn't a Business</h2>
Not everyone is applauding DOGE's aggressive cuts. Billionaire investor Mark Cuban recently <a href="https://www.benzinga.com/personal-finance/25/03/44484549/mark-cuban-on-doge-government-cuts-this-isnt-a-corporate-turnaround-this-is-the-united-states-of-america">warned that rushing to slash government programs</a> could cause more harm than good.
&#8220;I am all for cutting gov costs, then and now. I'm even more for efficiency,&#8221; Cuban <a href="https://x.com/realchrisrufo/status/1902787469625659629">wrote</a> on X. &#8220;I would have a plan. Ready Fire Aim is not a plan.&#8221;
He stressed that many cities rely heavily on federal jobs, and sudden mass layoffs could damage local economies, housing markets and essential services. &#8220;How many people will lose their jobs and homes because this was done ALL AT ONCE?&#8221; Cuban asked.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

You're Not A Good American If You're Against DOGE, Says Grant Cardone, Slamming Critics Of Musk And His Agency

Johnson Controls Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) short percent of float has fallen 4.55% since its last report. The company recently reported that it has 9.47 million shares sold short, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Johnson Controls Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743438627_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson Controls Intl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Johnson Controls Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Johnson Controls Intl's peer group average for short interest as a percentage of float is 4.29%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Johnson Controls Intl's Recent Short Interest

Nutanix's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NYSE">NTNX</a>) short percent of float has fallen 12.57% since its last report. The company recently reported that it has 7.50 million shares sold short, which is 3.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Nutanix Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743438622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nutanix has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Nutanix's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Nutanix's peer group average for short interest as a percentage of float is 3.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NTNX

How Do Investors Really Feel About Nutanix?

Press Releases

Presidio Property Trust Announces Series D Preferred Stock Cash Dividend

Earnings

Real Estate

Presidio Property Trust, Inc. Announces Earnings for the Second Quarter Ended June 30, 2024

Presidio Property Trust Provides Update on Model Home Activity in Q3 2024

Presidio Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Presidio Property Trust Announces Update of Share Repurchase Program

Presidio Property Trust Provides Update on Model Home Activity in Q4 2024

Presidio Property Trust Announces Sales of Union Town Center and Research Parkway Properties

Presidio Property Trust Provides Update on Real Estate Activity in January and February 2025

SQFT

SQFTP

SQFTW

American Assets Trust

Armada Hoffler Properties, Inc. Common Stock

Armada Hoffler Properties

Alexander & Baldwin, Inc. Common Stock REIT Holding Company

Alexander & Baldwin

Broadstone Net Lease

CTO Realty Growth

Essential Properties Realty Trust, Inc. Common Stock

Essential Properties

Empire State Realty OP, L.P. Series ES Operating Partnership Units Representing Limited Partnership Interests

Empire State Realty OP

Empire State Realty Trust, Inc. Class A Common Stock

Empire State Realty Trust

Generation Income Properties Inc. - Common stock

Generation Income

Global Net Lease

Gladstone Commercial Corporation - Real Estate Investment Trust

Gladstone Commercial

Medalist Diversified REIT, Inc. - Common Stock

Medalist Diversified REIT

Modiv Industrial, Inc. Class C Common Stock

Modiv Industrial

MacKenzie Realty Capital, Inc. - Common Stock

Mackenzie Realty Capital

NexPoint Diversified Real Estate Trust Common Stock

NexPoint Diversified Real

One Liberty Properties, Inc. Common Stock

One Liberty Properties

Alpine Income Property Trust, Inc. Common Stock

Comments

Presidio Property Trust

空売り

Presidio Property Trust (NASDAQ:SQFTP) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル